medication

We Haven’t Scratched the Surface of Weight-Loss Drug Advances

By / , , , /

Orforglipron is an oral drug from Eli Lilly that’s in trial stage. The New York Times reports that in a trial of over 500 patients, those “who took the highest dose lost an average of around 16 pounds after nine months.” The Times added that roughly “two-thirds of people who took the drug also saw their blood sugar […]

We Haven’t Scratched the Surface of Weight-Loss Drug Advances Read More »

Pancreatic Cancer, Daraxonrasib, and the Suffocation of Knowledge

By / , , /

In the seriously great news department, pancreatic cancer is expected to pass colorectal cancer as the second biggest cause of cancer-related death by 2030. Yes, it’s great news. To see why, look back to the beginning of the mid-19th century. At the time tuberculosis and pneumonia killed far more Americans than surely lethal cancer in

Pancreatic Cancer, Daraxonrasib, and the Suffocation of Knowledge Read More »

Scroll to Top